OBJECTIVE： To evaluate the effectiveness and safety of Shenqi fuzheng injection assisting TACE in the adjuvant treatment of primary liver carcinoma， and to provide evidence-based reference. METHODS： Retrieved from CJFD， Wanfang database， VIP and PubMed， randomized controlled trials （RCTs） about Shenqi fuzheng injection assisting TACE （trial group） vs. TACE alone （control group） in the treatment of primary liver carcinoma were collected. Meta-analysis was performed by using Stata 12.0 software after data extraction and quality evaluation according to improved Jadad scale. RESULTS： A total of 8 RCTs were included， involving 527 patients. Results of Meta-analysis showed that there was no statistical significance in response rate [RR＝1.19，95％CI（0.97，1.46），P＝0.091] and clinical benefit rate [RR＝1.16，95％CI（0.90，1.48），P＝0.251] of 2 groups. The rate of life quality improvement in trial group was significantly higher than control group [RR＝2.26，95％CI（1.64，3.10），P＝0.001]， while the incidence of above middle fever [RR＝0.74，95％CI（0.63，0.88），P＝0.001]， gastrointestinal reaction [RR＝0.52，95％CI（0.32，0.85），P＝0.010] and leucocyte reduction rate [RR＝0.75，95％CI（0.62，0.92），P＝0.005]， were significantly lower than control group， with statistical significance. CONCLUSIONS： Shenqi fuzheng injection assisting TACE for primary liver carcinoma cannot improve therapeutic efficacy but improve the quality of life and reduce the incidence of gastrointestinal reaction and leucocyte reduction.